Moonlake Immunotherapeutics (MLTX) Reiterated at Overweight by Cantor Fitzgerald Mar 3, 2026 07:00AM
Cantor Fitzgerald Reiterates Overweight Rating on Moonlake Immunotherapeutics (MLTX) Apr 4, 2025 07:16AM
Acelyrin (SLRN) crashes 60% as lead product misses in study; Seen as a 'big positive' for MoonLake (MLTX) Sep 12, 2023 06:39AM
MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update Aug 10, 2023 07:00AM
MoonLake Immunotherapeutics (MLTX) Prices 8M Share Offering at $50/sh Jun 28, 2023 05:14AM


Jun 28, 2023 05:00AM MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares
Jun 26, 2023 04:02PM MoonLake Immunotherapeutics (MLTX) Announces Proposed Underwritten Public Offering
Jun 26, 2023 04:01PM MoonLake Immunotherapeutics Announces Proposed Underwritten Public Offering
Jun 26, 2023 03:47PM MoonLake jumps 100% on impressive Phase 2 MIRA trial results, analysts react